Pneumonia Vaccine in Aging HIV Positive Individuals

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions
Pneumococcal Infection
Interventions
BIOLOGICAL

23-valent pneumococcal polysaccharide vaccine

One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine

BIOLOGICAL

13-valent pneumococcal conjugate vaccine

One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.

Trial Locations (1)

43614

The University of Toledo-Health Science Campus, Toledo

All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

lead

University of Toledo Health Science Campus

OTHER

NCT02558751 - Pneumonia Vaccine in Aging HIV Positive Individuals | Biotech Hunter | Biotech Hunter